ArticleMethodsX2023
iMIGS: An innovative AI based prediction system for selecting the best patient-specific glaucoma treatment.
Article in MethodsX, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuro-fuzzy systems in internet of medical things: a systematic review on applications, taxonomy, challenges and open issues.Frontiers in digital health · 2026Review
- Advancing Glaucoma Care: Integrating Artificial Intelligence in Diagnosis, Management, and Progression Detection.Bioengineering (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of AI-based techniques in healthcare are becoming more and more common and more disease-specific. Glaucoma is a disorder in eye that causes damage to the optic nerve which can lead to permanent blindness. It is caused by the elevated pressure inside the eye due to the obstruction to the flow of the drainage fluid (aqueous humor). Most recent treatment options involve minimally invasive glaucoma surgery (MIGS) in which a stent is placed to improve drainage of aqueous humor from the eye. Each MIGS surgery has a different mechanism of action, and the relative efficacy and chance of success is dependent on multiple patient-specific factors. Hence the ophthalmologists are faced with the critical question; which method would be better for a specific patient, both in terms of glaucoma control but also taking into consideration patient quality of life? In this paper, an Adaptive Neuro-Fuzzy Inference System (ANFIS) has been developed in the form of a Treatment Advice prediction system that will offer the clinician a suggested MIGS treatment from the baseline clinical parameters. ANFIS was used with a real-world MIGS data set which was a retrospective case series of 372 patients who underwent either of the four MIGS procedures from July 2016 till May 2020 at a single center in the UK.•Inputs used: Clinical measurements of Age, Visual Acuity, Intraocular Pressure (IOP), and Visual Field, etc.•Output Classes: iStent, iStent and Endoscopic Cyclophotocoagulation (ICE2), PreserFlo MicroShunt (PMS) and XEN-45).•Results: The proposed ANFIS system was found to be 91% accurate with high Sensitivity (80%) and Specificity (90%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.